Recently, the genetic industry has continued to do so. After entering the New Year, 2016 is the first year of precision medicine . No matter how many industry people are watching the hot words, or the capital industry's fierce attack on precision medical occupation, it is worthy of our attention in the precise medical layout, but it is the three major players who may enter the capital game in the future. .
The first big player, deservedly belongs to the drug name Kant.
The drug name Kang Decon first announced its privatization to completion in August 2015, and it only took four months. On December 10th, US time, Wuxi WuXi PharmaTech announced that it had completed its privatization after the close of the day and delisted from the NYSE with a market capitalization of US$3.3 billion. WuXi PharmaTech will be sold to the newly established parent company New WuXi Life Science Limited, which will form WuXiMerger Limited, a wholly-owned subsidiary of the newly established parent company. The transaction price is $46 per share. This price is a 16.5% premium to the closing price of the previous day of WuXi PharmaTech's privatization plan ($39.50).
The privatization of the drug name Kant is only the first step of the Long March. Whether it is returning to A shares is not a goal worthy of expectation. What makes the people more curious is that from the initial team of only 4 people in 2000 to the ranks of the global drug research and development giants, the name of the drug with more than 10,000 employees will be in the future. I believe that Mr. Li Ge, who returned to China 16 years ago, must have started research and development of new drugs. At this moment, Li Ge, with a team of tens of thousands of people and a valuation of nearly 20 billion yuan, is not satisfied with research and development services alone, but creates an open platform that may become a biopharmaceutical industry. Inside "Alibaba" or "Amazon." Once this strategic positioning is formed, the drug name Kant will begin to have a series of attacks in the direction of precision medicine.
What will be the emergence of this series of attacks? To guess the next step for industry players, let's take a look at the money spent on this business in the past year or two:
The group that WuXi PharmaTech proposed to privatize includes venture capital institutions such as Huiqiao Capital Group and Boyu Investment, as well as institutions of Ping An Insurance Group and Singapore Temasek Holdings. In the past two years, the investment field of the drug name Kant has focused on genetic science, including biological services such as cell therapy, and mobile medicine .
If it is said that the beginning of spending money is the bureau, then the habit of using money in the future will be the routine of the enterprise. It is not difficult to predict that the next step of the drug name Kant will be to step forward in the establishment of investment funds, spin-off business segment, backdoor listing, entering the genetic industry, and exploring new possibilities for research and development of new drugs.
Once the drug name Kant takes the first step of such a simple strategy, it will inevitably confront the leading players in the genetic industry.
The second largest player is the leading gene in the genetic industry.
In the official interpretation of Huada, "Hua Da" literally understood as "China is big." But in fact, the name is the spark of Wang Jian, the chairman of Huada Gene, when he was driving a red light. Why is it called Huada? There is a couplet in Huada that may be able to tell the truth. Shanglian is the pride of Huaxia, and it is a great foundation for science. The lower league is the elite of the big country, and the life of the same life is the same; the horizontal batch is a long way to go.
The Huada Gene is destined to be the spark of this wisdom. There is no second Wang Jian in the world, nor will there be a second Huada gene. Huada has become a brand. Apart from the many “Huaxiao†and “Huadian†left, there is more historical responsibility. Perhaps, this is Wang Jian’s one-person war, the team, just a magnification of his local ability.
The story of the listing of Huada Gene can no longer satisfy more curiosity. What deserves our concern is whether this decomposed behemoth can form a good ecology. It is worth mentioning that Huada Gene has no experience in biopharmaceuticals, and its clinical application is just as good as that of traditional CRO companies. The industry, which holds the technology of "secret weapon" gene sequencing technology for precision medicine, has made great progress toward the clinic.
Soy Sauce,Soy Sauce For Resturant,Raw Sauce Soy Sauce,Soy Sauce Seasonings
Chinese Seasoning (Shandong) Trading Co.,Ltd , https://www.zt-trading.com